Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus vs placebo for tocilizumab-resistant idiopathic multicentric Castleman disease
jRCT2071190029Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in idiopathic multicentric Castleman disease (iMCD) comparing Sirolimus arm with Placebo arm (2 arms). Primary endpoint: Primary endpoint - CHAP score response at 16 weeks. Started May 2020; status: completed.
02
Drugs
sirolimus
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on jRCT2071190029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071190029.